Mumbai, Feb. 27 -- The EIR follows an inspection conducted at the site from 10 November to 21 November, 2025, confirming compliance with regulatory standards.

Nilesh Gupta, managing director (MD), Lupin, stated, "We are pleased to have received the EIR with a VAI classification from the US FDA for our Goa facility. This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide."

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology produc...